Januvia

An array of relatively newly approved, expensive therapies for diabetes complicates decision making with regard to treatment. A drug preventing the body from degrading incretin helps keep levels of insulin high while reducing concentrations of glucagon, a hormone intimately linked to boosting blood sugar. With a daily cash price of about $16, it lowers hemoglobin A1c, HbA1c, by a relatively small amount. Some experts wonder if the hefty price tag of these new therapies can be justified when advantages over traditional options often appear sketchy or non-existent.